ClinicalTrials.gg
RecruitingNCT06406790Updated Feb 20, 2026

CraniSeal Post Approval Study

A Phase 4 interventional study of CraniSeal and DuraSeal in Leak, Cerebrospinal Fluid, sponsored by Pramand LLC. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Pramand LLC · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Cerebrospinal Fluid Leak with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Cerebrospinal Fluid Leak · United States.

Started
2024
the only one that year
Phase 4
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
1 of 12
Pramand LLC

Among the 12 studies in Cerebrospinal Fluid Leak with a site in United States, this one is the only one that started in 2024, is the only one in phase 4, and was the 12th registered.

Cerebrospinal Fluid Leak

41 studies on the registry are indexed under Cerebrospinal Fluid Leak; 9 are open to participants now.

Browse Cerebrospinal Fluid Leak studies →

Open to participants now

2 of the 12 studies in Cerebrospinal Fluid Leak with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Cerebrospinal Fluid Leak studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cerebrospinal Fluid Leak with a site in United States, or all of them as a file.
02

Study summary

To collect post-approval data comparing the safety and effectiveness of CraniSeal Dural Sealant to DuraSeal Dural Sealant. The study has been powered specifically to determine whether the CraniSeal device when used as an adjunct to sutured dural closure following elective cranial surgery is no worse than (i.e., non-inferior) to the DuraSeal device with respect to proportion of subjects free from post-operative cerebrospinal fluid (CSF) leaks. Additional safety outcomes (i.e., surgical site infections and adverse events/device-related adverse events) will also be captured and compared.

03

Conditions studied

  • Leak, Cerebrospinal Fluid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  1. Patient is ≥ 18 years of age
  2. Patient is scheduled for an elective infratentorial or supratentorial cranial procedure under general anesthesia that entails a dural incision
  3. Patient requires a procedure involving surgical wound classification Class I/Clean
  4. Patient signs a written form to participate in the study, prior to any study mandated determinations or procedures.
  5. Patients who are able to comply with study requirements.

General Exclusion Criteria:

  1. Patient requires a procedure involving translabyrinthine, transsphenoidal, transoral and/ or any procedure that penetrates the air sinus or mastoid air cells; superficial penetration of air cells are not excluded
  2. Patient has had a prior intracranial neurosurgical procedure in the same anatomical location
  3. Patient with diagnosis of severely altered renal (creatinine levels > 2.0 mg/dL) or hepatic (total > 2.5 mg/dL) function
  4. Patient diagnosed with a compromised immune system or disease (WBC count less than 4000/uL or greater than 20,000/uL)
  5. Patients undergoing cranial procedures involving petrous bone drilling
  6. Patients with traumatic injuries to the head or dural disease in planned dural closure area
  7. Patients who are pregnant or lactating
  8. Patient with an active infection
  9. Patient is undergoing cranial procedures involving non-autologous duraplasty material that are not collagen based
  10. Patients requiring re-opening of planned surgical area within 90 days after surgery.
  11. Patient with a known allergy to FD\&C Blue #1 dye
  12. Patient is not able to tolerate multiple Valsalva maneuvers, or transient elevation of CSF pressure during Valsalva maneuvers is not possible (e.g. the presence of a temporary or permanent CSF shunt
  13. Presence of hydrocephalus
  14. Patient with a diagnosis of uncontrolled diabetes (e.g., persistent elevation of >9% despite standard diabetes care),
  15. Patient has a documented, uncorrectable coagulopathy (e.g., >37 seconds or INR >1.5 units)
  16. Patient is not likely to comply with the follow-up evaluation schedule.
  17. to both an MRI and CT scan.
  18. Patients participating in any device study within 30 days or currently receiving an investigational drug/biologic therapy. (Observational studies on FDA approved products are not applicable)
  19. Patients diagnosed with Meningiomatosis (multiple meningiomas)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    CraniSeal

    CraniSeal

    Device: CraniSeal

  • Active comparator
    DuraSeal

    DuraSeal

    Device: DuraSeal

Interventions

  • DeviceCraniSeal

    CraniSeal is a PEG Dural Sealant

  • DeviceDuraSeal

    DuraSeal is a PEG Dural Sealant

06

What researchers measure

Primary outcomes

  1. Absence of CSF Leaks

    absence of CSF leaks on study

    Time frame: 90 days

Other outcomes

  1. TEAEs and TESAEs

    treatment emergent events on study

    Time frame: 90 days

07

Study locations

7 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Feb 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartActual
May 29, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06406790
Lead sponsor
Pramand LLC
Responsible party
Sponsor
First posted
May 9, 2024
Start date
May 29, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

M Pace
Contact
mike.pace@pramandllc.com
6172335873

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion